Palatin Technologies, Inc. (PTN) Stock Score, Valuation & Financial Research

Palatin Technologies, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 29/100.

Quick answer for PTN

Palatin Technologies, Inc. currently has a Wall Street Score of 29/100. The stored market price is USD 7.42. Its financial score is 24/100. Its valuation score is 0/100. The latest WSS change is +0.6 points. These figures are a research snapshot, not a buy or sell recommendation.

What Palatin Technologies, Inc. does

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Company business and revenue

Research reporting period: 2026-06-30. A research update is not a new financial filing.

How the company makes money

Palatin Technologies is a biopharmaceutical company that focuses on the development of targeted, receptor-specific therapeutics based on the melanocortin receptor system. The company's business model relies on developing product candidates through clinical trials and subsequently entering into licensing or marketing collaborations with industry partners to commercialize these assets and generate revenue through milestone payments and royalties.

Products and services

The company develops melanocortin receptor-targeted therapeutics, including Vyleesi for HSDD, PL9643 for dry eye disease, and bremelanotide combinations for erectile dysfunction.

Brands and product families

Vyleesi — An FDA-approved melanocortin agent for the treatment of hypoactive sexual desire disorder in premenopausal women. Source

Customer types

Pharmaceutical and biotechnology industry partners.

Suppliers, materials and equipment

Contract Research Organizations (CROs) — The company utilizes various unnamed third-party contract research organizations to conduct clinical trials and preclinical studies. Source
Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party contract manufacturers for the production of drug substances and drug products for clinical and commercial use. Source

Business relationships and partnerships

Boehringer Ingelheim International GmbH — A licensing and acquisition agreement where Boehringer Ingelheim acquired certain Palatin patent applications related to melanocortin receptor-targeted peptides for retinal diseases and glaucoma. Source

Business strengths to evaluate

Proprietary expertise in the melanocortin receptor system Source

Business risks and research considerations

Dependence on third-party manufacturers and clinical research organizations Source
History of operating losses and need for additional capital Source

Sources: Company research source · Vyleesi · Boehringer Ingelheim International GmbH · Proprietary expertise in the melanocortin receptor system

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PTN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: 29/100
Stored price:: USD 7.42
Market capitalization:: 13.21M (currency not supplied)
Revenue:: USD 13.19M
Net income:: USD -8.38M
Free cash flow:: USD -13.58M
Cash:: USD 7.49M
Total debt:: USD 223.68K
EPS:: USD -5.25
Financial score:: 24/100
Valuation score:: 0/100
Revenue score:: 30/100

What stands out

Reported year-over-year revenue growth is +0.0%.
Free cash flow is USD -13.58M, negative for the stored period.
The balance sheet shows USD 7.49M of cash versus USD 223.68K of total debt, an excess of cash over debt on these two reported measures.
The latest Wall Street Score change is +0.6 points: PTN increased 0.6 points because Asset improved by 3.5 points.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Free cash flow is -103.0% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
Net income equals -63.5% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
Cash exceeds debt by USD 7.27M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PTN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

Can PTN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
How long can PTN fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is PTN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for PTN to reach sustainable profitability?
What future growth or profitability would be needed to justify PTN's current valuation?

What the numbers mean

Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.

The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 100% of the scoring inputs required for this public page are currently available.

How to research PTN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.